Articoli
https://www.newence.com/wp-content/uploads/2019/09/GL-esc-2019.jpg
811
1812
Redazione Newence
https://www.newence.com/wp-content/uploads/2016/10/newence_logo.png
Redazione Newence2019-09-25 09:00:462019-09-22 16:10:20Le nuove linee Guida 2019 dell’ESC. Parte 2: le dislipidemie
https://www.newence.com/wp-content/uploads/2017/09/Cholesterol-mod.jpg
368
559
Franco Folino
https://www.newence.com/wp-content/uploads/2016/10/newence_logo.png
Franco Folino2018-12-06 05:00:272018-12-01 16:22:45Alirocumab riduce gli eventi cardiovascolari ricorrenti nei pazienti con sindrome coronarica acuta
https://www.newence.com/wp-content/uploads/2017/04/AHA-e-ACC.jpg
506
800
Franco Folino
https://www.newence.com/wp-content/uploads/2016/10/newence_logo.png
Franco Folino2018-11-12 05:00:212018-11-12 13:57:29Le nuove linee guida AHA/ACC 2018 sulla gestione del colesterolo
https://www.newence.com/wp-content/uploads/2016/10/emboli.jpg
315
700
Franco Folino
https://www.newence.com/wp-content/uploads/2016/10/newence_logo.png
Franco Folino2018-11-11 05:00:382018-11-09 11:08:28Sindrome coronarica acuta: con un inibitore del PCSK9 (alirocumab) si riduce il rischio di nuovi eventi CV
https://www.newence.com/wp-content/uploads/2017/07/farmaci-5.jpg
638
960
Redazione Newence
https://www.newence.com/wp-content/uploads/2016/10/newence_logo.png
Redazione Newence2018-08-17 05:00:312018-08-04 16:10:13Sempre più in basso: i benefici di un colesterolo LDL a 21 mg/dL
https://www.newence.com/wp-content/uploads/2018/04/Senzanome.jpg
400
640
Franco Folino
https://www.newence.com/wp-content/uploads/2016/10/newence_logo.png
Franco Folino2018-04-20 05:00:492018-04-20 18:05:17Maggiori benefici clinici dal trattamento ipolipemizzante se i livelli basali di LDL superano i 100mg/dL
https://www.newence.com/wp-content/uploads/2017/10/Sistema-circulatorio.jpg
501
640
Franco Folino
https://www.newence.com/wp-content/uploads/2016/10/newence_logo.png
Franco Folino2017-10-30 05:00:542017-10-28 18:34:55Una soglia impensabile. Abbassare il colesterolo LDL a meno di 10mg/dl per ridurre ulteriormente gli eventi cardiovascolari
https://www.newence.com/wp-content/uploads/2017/10/GISE-tolove-expert.jpg
321
663
Franco Folino
https://www.newence.com/wp-content/uploads/2016/10/newence_logo.png
Franco Folino2017-10-17 05:00:072017-10-10 18:15:15Expert Focus dal congresso GISE TOLOVE: gli inibitori del PCSK9. Intervista con il Dr. D. D’Andrea
https://www.newence.com/wp-content/uploads/2017/08/bilancia-statine.jpg
1359
2005
Franco Folino
https://www.newence.com/wp-content/uploads/2016/10/newence_logo.png
Franco Folino2017-08-18 05:00:442017-08-08 11:05:32Il trattamento delle ipercolesterolemie: conta di più il rischio cardiovascolare o il livello di colesterolo?
https://www.newence.com/wp-content/uploads/2016/06/MED-stent-grant-copy.jpg
720
1280
Franco Folino
https://www.newence.com/wp-content/uploads/2016/10/newence_logo.png
Franco Folino2017-03-22 05:38:052017-03-19 12:47:48Evolocumab riduce gli eventi cardiovascolari anche nei pazienti con bassi livelli di LDL